Smith & Nephew (SNN) – Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Smith & Nephew (NYSE: SNN):

  • 2/9/2018 – Smith & Nephew was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 2/8/2018 – Smith & Nephew had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They wrote, “We reiterate our BUY rating and $45 PT following Q4/17 sales results. Sales in the quarter were supported by strong global knee sales driven by above- market growth of Journey II in the US and Anthem in emerging markets. In recon we also highlight encouraging early momentum for Navio with management noting a ~50% increase in system sales, 500 surgeons trained in the US, and Navio accounts showing 2x growth in knees. While still early (2017 was the first full year of TKA launch) strong momentum in knees/Navio is encouraging given knees represent ~20% of overall revenue mix on a historical basis. Guidance came in a bit light relative to expectations — something we view as a conservative move given the pending CEO change. In sum, we reiterate our thesis that SNN is positioned to surprise investors in 2018 with a product portfolio capable of delivering accelerating growth and upside to profitability metrics.””
  • 2/7/2018 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 1/25/2018 – Smith & Nephew was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating.
  • 1/5/2018 – Smith & Nephew had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $45.00 price target on the stock.

Shares of Smith & Nephew plc (NYSE SNN) traded up $0.48 on Monday, hitting $35.06. The company’s stock had a trading volume of 326,411 shares, compared to its average volume of 595,386. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 2.03. Smith & Nephew plc has a 52-week low of $30.11 and a 52-week high of $40.43.

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply